CIK 0001937653 · Non-accelerated filer<br>Smaller reporting company
Zymeworks Inc.
Sign in to watch- Ticker
- ZYME
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 883099146
- Phone
- 302-274-8744
- Business address
- 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN, DE, 19709
- Former names
- Zymeworks Delaware Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $357,557
- in 1 filing
Net −$357,557. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-12 | Moore Paul Andrew Chief Scientific Officer | Option exercise · Restricted Stock Unit | −17,666 | 35,334 | ||
| 2026-01-12 | Moore Paul Andrew Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +70,000 | 70,000 | ||
| 2026-01-12 | Moore Paul Andrew Chief Scientific Officer | Grant or award · Restricted Stock Unit | +47,000 | 47,000 | ||
| 2026-01-12 | Moore Paul Andrew Chief Scientific Officer | Grant or award · Performance Stock Unit | +66,000 | 66,000 | ||
| 2026-01-12 | Galbraith Kenneth Chair & CEO | Option exercise | +64,000 | 257,266 | ||
| 2026-01-12 | Galbraith Kenneth Chair & CEO | Sale | −30,424 | $22.67 | $690K | 226,842 |
| 2026-01-12 | Galbraith Kenneth Chair & CEO | Option exercise · Restricted Stock Unit | −64,000 | 128,000 | ||
| 2026-01-12 | Galbraith Kenneth Chair & CEO | Grant or award · Stock Option (Right to Buy) | +216,000 | 216,000 | ||
| 2026-01-12 | Galbraith Kenneth Chair & CEO | Grant or award · Restricted Stock Unit | +144,000 | 144,000 | ||
| 2026-01-12 | Galbraith Kenneth Chair & CEO | Grant or award · Performance Stock Unit | +222,000 | 222,000 | ||
| 2026-01-06 | PATTERSON LEONE D EVP, Chief Bus & Fin Officer | Grant or award | +459 | $10.55 | $5K | 459 |
| 2026-01-05 | Smith Jeffrey T L EVP & Chief Medical Officer | Option exercise | +20,000 | 28,890 | ||
| 2026-01-05 | Smith Jeffrey T L EVP & Chief Medical Officer | Sale | −10,538 | $25.10 | $264K | 18,352 |
| 2026-01-05 | Smith Jeffrey T L EVP & Chief Medical Officer | Option exercise · Restricted Stock Unit | −20,000 | 20,000 | ||
| 2026-01-05 | Galbraith Kenneth Chair & CEO | Option exercise | +47,668 | 180,943 | ||
| 2026-01-05 | Galbraith Kenneth Chair & CEO | Sale | −22,657 | $25.10 | $569K | 158,286 |
| 2026-01-05 | Galbraith Kenneth Chair & CEO | Option exercise | +66,666 | 224,952 | ||
| 2026-01-05 | Galbraith Kenneth Chair & CEO | Sale | −31,686 | $25.10 | $795K | 193,266 |
| 2026-01-05 | Galbraith Kenneth Chair & CEO | Option exercise · Restricted Stock Unit | −47,668 | 0 | ||
| 2026-01-05 | Galbraith Kenneth Chair & CEO | Option exercise · Restricted Stock Unit | −66,666 | 66,668 |
Page 3 of 12 · 224 trades